Status:
UNKNOWN
The Effect of Warm Compress Therapy Using the TearRestore Eyelid Warming Mask on Meibomian Gland Function
Lead Sponsor:
University of Colorado, Denver
Conditions:
Meibomian Gland Dysfunction
Eligibility:
All Genders
18-89 years
Phase:
NA
Brief Summary
This study plans to learn more about the effectiveness of the TearRestore eyelid warming mask on signs and symptoms of Meibomian Gland Dysfunction (MGD). MGD is a leading cause of dry eye symptoms. Wa...
Detailed Description
The study will evaluate the effectiveness of the TearRestore eyelid warming mask on signs and symptoms of MGD. Warm compress treatments have been recommended as part of the standard of care by eye phy...
Eligibility Criteria
Inclusion
- Adult participants (age 18-89) of any race, gender or ethnicity, diagnosed with meibomian gland dysfunction
- Symptom score greater than eight on the SPEED questionnaire
- Less than 75nm lipid layer thickness (LLT) utilizing the Lipiview II
- Less than 10 second tear break up time (average of 3 measurements)
Exclusion
- Participants with less than 6/15 meibomian glands yielding liquid secretions in either eyelid
- Diagnosed with a systemic autoimmune condition including but not limited to Sjogren's or Lupus
Key Trial Info
Start Date :
November 20 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04309799
Start Date
November 20 2020
End Date
February 1 2023
Last Update
February 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado, Dept. of Ophthalmology
Aurora, Colorado, United States, 80045